Corylus Avellana Pollen

Dosage for Corylus Avellana Pollen is highly individualized and is not based on a standard 'one-size-fits-all' milligram dose. Instead, it is measured in Weight/Volume (w/v) or Protein Nitrogen Units (PNU), as it is a non-standardized extract.

For Diagnostic Testing

• Skin Prick Test: A single drop of the concentrated extract (typically 1:10 or 1:20 w/v) is applied to the skin, followed by a light puncture. Results are read after 15–20 minutes.
• Intradermal Test: If the prick test is negative, 0.02 mL of a 1:1000 or 1:500 w/v dilution may be injected into the dermis.

For Immunotherapy (SCIT)

• Build-up Phase: Treatment usually begins with a very low dose (e.g., 0.1 mL of a 1:100,000 w/v dilution). Doses are increased weekly or bi-weekly by 50–100% until the 'Maintenance Dose' is reached. This phase typically lasts 3 to 6 months.
• Maintenance Phase: Once the highest tolerated dose is reached (the maintenance dose), the interval between injections is increased to every 2 to 4 weeks. Maintenance therapy usually continues for 3 to 5 years to achieve long-term desensitization.

Corylus Avellana Pollen is generally considered safe for use in children, typically aged 5 years and older. Dosing protocols for children are identical to adult protocols, as the dose is determined by the individual's level of sensitivity rather than body weight. However, immunotherapy is rarely initiated in children under the age of 5 due to the difficulty of communicating symptoms of an impending systemic reaction.

Renal Impairment

No dosage adjustments are required for patients with renal impairment, as the extract is not cleared by the kidneys in its active form.

Hepatic Impairment

No dosage adjustments are necessary for patients with hepatic impairment.

Elderly Patients

Caution should be exercised in elderly patients, particularly those with underlying cardiovascular disease. The dose itself does not change, but the risk-benefit ratio must be carefully evaluated due to the potential danger of using epinephrine (the treatment for anaphylaxis) in patients with heart conditions.

Corylus Avellana Pollen extract is never self-administered by the patient at home. It must be administered in a clinical setting (physician's office or infusion center) by healthcare professionals equipped to treat anaphylaxis.

• Administration Route: Subcutaneous injection (usually in the posterior aspect of the upper arm).
• Observation Period: Patients must remain in the clinic for at least 30 minutes following every injection to monitor for systemic reactions.
• Storage: Vials must be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). Do not freeze.

If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on how much time has passed. If a maintenance dose is missed by more than 1-2 weeks, the physician will typically reduce the dose for the next injection to ensure safety.

An 'overdose' in the context of immunotherapy refers to an injection of a dose higher than the patient's current tolerance level. This can lead to a severe systemic allergic reaction.

• Signs: Hives, swelling of the throat, wheezing, low blood pressure, or rapid heart rate.
• Emergency Measures: Immediate administration of epinephrine (0.3 mg IM for adults), oxygen, IV fluids, and potentially antihistamines or corticosteroids.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most patients undergoing immunotherapy with Corylus Avellana Pollen will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Injection Site Redness (Erythema): A pink or red area around the injection site, typically appearing within minutes and lasting several hours.
• Swelling (Edema): A raised bump or wheal at the site. If the swelling is larger than a half-dollar (approx. 3 cm), your doctor may adjust your next dose.
• Itching (Pruritus): Intense itching at the site of injection or skin testing.
• Tenderness: The arm may feel sore or 'heavy' for 24 hours after the injection.

• Generalized Hives (Urticaria): Itchy welts appearing on parts of the body other than the injection site.
• Fatigue: Some patients report feeling unusually tired for a few hours following an immunotherapy session.
• Mild Nasal Congestion: A temporary 'flare' of hay fever symptoms shortly after the injection.

• Laryngeal Edema: Swelling of the throat or larynx, causing difficulty swallowing or a 'lump in the throat' sensation.
• Bronchospasm: Tightening of the airways leading to wheezing and shortness of breath.
• Hypotension: A sudden drop in blood pressure, which may cause dizziness or fainting.

> Warning: Stop taking Corylus Avellana Pollen and call your doctor immediately if you experience any of these symptoms of Anaphylaxis:

• Difficulty Breathing: Wheezing, chest tightness, or a persistent cough.
• Swelling of the Face or Tongue: Angioedema that may obstruct the airway.
• Rapid or Weak Pulse: Signs of cardiovascular distress.
• Dizziness or Loss of Consciousness: Indicating a severe drop in blood pressure (anaphylactic shock).
• Nausea or Vomiting: Sudden gastrointestinal distress following an injection is often a sign of a systemic reaction.

There are no known long-term 'toxic' effects of Corylus Avellana Pollen extracts. Unlike many medications, immunotherapy is designed to have a long-term positive effect on the immune system. However, if a patient develops a new autoimmune condition or significant change in health status, the continuation of immunotherapy should be re-evaluated.

While specific 'Black Box' warnings are often associated with sublingual immunotherapy (SLIT) tablets, all injectable allergenic extracts carry a strong warning regarding the risk of Severe Systemic Reactions.

• Anaphylaxis Risk: Corylus Avellana Pollen can cause life-threatening anaphylaxis. It must only be administered in settings where emergency resuscitation equipment and trained staff are immediately available.
• Asthma Warning: Patients with unstable or poorly controlled asthma are at a significantly higher risk for fatal reactions and should not receive immunotherapy until their asthma is stabilized.

Report any unusual symptoms to your healthcare provider.

Corylus Avellana Pollen is a potent biological agent. The most critical safety consideration is the risk of a systemic allergic reaction. Patients must be 'clinically stable' on the day of their injection. If you are experiencing an active asthma flare or a severe infection, your injection should be postponed.

No FDA black box warnings for Corylus Avellana Pollen injectable extracts specifically, but they are governed by the general safety requirements for all allergenic extracts. These requirements mandate that the product be used only by physicians experienced in respiratory diseases and allergy, and that patients be monitored for at least 30 minutes post-injection.

• Anaphylaxis Risk: This is the primary concern. Patients should be educated on the signs of anaphylaxis and may be required to carry an epinephrine auto-injector (e.g., EpiPen) at all times during the course of treatment.
• Asthma Status: If your FEV1 (Forced Expiratory Volume) is below 70% of your predicted value, or if you have had a recent asthma exacerbation, the risk of a severe reaction to the extract is greatly increased.
• Cardiovascular Disease: Patients with significant heart disease may not be able to tolerate the physiological stress of a systemic reaction or the effects of the epinephrine used to treat it.

There are no specific laboratory tests (like blood counts or liver enzymes) required for Corylus Avellana Pollen. However, clinical monitoring is intensive:

• Pre-Injection Check: Your provider will ask about your current symptoms and any reactions to the previous dose.
• Post-Injection Observation: A mandatory 30-minute wait in the clinic.
• Peak Flow Meter: Asthma patients may be asked to perform a peak flow test before receiving their injection.

Generally, Corylus Avellana Pollen does not cause sedation. However, if you experience a systemic reaction or feel lightheaded after an injection, you should not drive until the symptoms have completely resolved and you have been cleared by your doctor.

Alcohol should be avoided on the day of your injection. Alcohol can cause vasodilation (widening of blood vessels), which may theoretically increase the rate of allergen absorption and heighten the risk or severity of a systemic reaction.

Immunotherapy can be stopped at any time, but doing so will result in the gradual return of allergy symptoms. There is no 'withdrawal syndrome' associated with stopping Corylus Avellana Pollen, but the progress made toward desensitization will be lost if the course is not completed (usually 3–5 years).

> Important: Discuss all your medical conditions with your healthcare provider before starting Corylus Avellana Pollen.

• Beta-Blockers (e.g., Propranolol, Atenolol, Metoprolol): These medications are often contraindicated in patients receiving immunotherapy. If a patient on a beta-blocker has an anaphylactic reaction to the pollen extract, the beta-blocker may prevent epinephrine from working effectively, making the reaction potentially fatal.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): These blood pressure medications may interfere with the body's ability to degrade kinins, potentially increasing the severity of an allergic reaction or causing more profound low blood pressure during anaphylaxis.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of epinephrine, which could be problematic if emergency treatment for a reaction is needed.

• Antihistamines (e.g., Cetirizine, Loratadine): While not dangerous, taking antihistamines can mask the 'warning signs' of a mild reaction (like itching or hives), which might lead the doctor to increase the dose too quickly. Conversely, some doctors prescribe daily antihistamines to improve tolerance of the injections.
• Other Immunotherapy: If you are receiving multiple different allergy shots (e.g., for mold, dust mites, and hazel pollen), they should be administered in different arms to help identify which extract caused a reaction if one occurs.

• Hazelnuts: Patients with Corylus Avellana Pollen allergy often have 'Oral Allergy Syndrome.' Eating hazelnuts shortly before or after an injection may increase the total 'allergen load' on the immune system and increase the risk of a reaction.
• High-Fat Meals: No direct interaction, but heavy meals can sometimes make the detection of gastrointestinal symptoms of anaphylaxis more difficult.

• St. John's Wort: May theoretically affect the metabolism of other medications used to treat reactions, though no direct interaction with the pollen extract exists.
• Feverfew or Butterbur: Often used for allergies, these should be disclosed to the doctor to ensure they do not mask symptoms.

• Allergy Blood Tests (IgE/RAST): Immunotherapy will eventually cause a decrease in skin test reactivity and may change the levels of specific IgE and IgG4 in the blood. This is an expected clinical outcome rather than an 'interference.'

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Corylus Avellana Pollen must NEVER be used in the following circumstances:

• Severe, Uncontrolled Asthma: Patients with a baseline FEV1 < 70% predicted or those who have had life-threatening asthma episodes. The risk of a fatal bronchospasm during a reaction is too high.
• Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months, as the heart may not tolerate a systemic reaction or epinephrine.
• History of Severe Reaction to This Specific Extract: If a patient has previously experienced near-fatal anaphylaxis from Corylus Avellana Pollen, further immunotherapy is usually contraindicated.

• Pregnancy (Initiation): Immunotherapy should generally not be started during pregnancy due to the risk of anaphylaxis causing fetal hypoxia (lack of oxygen). However, if a woman is already on a stable maintenance dose, it is often continued.
• Autoimmune Disorders: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis may have unpredictable immune responses.
• Malignancy: Patients undergoing active chemotherapy or with certain cancers may have compromised immune systems that make immunotherapy less effective or more risky.

Patients allergic to Corylus Avellana Pollen are highly likely to be cross-sensitive to:

• Birch Pollen (*Betula*)
• Alder Pollen (*Alnus*)
• Hornbeam Pollen (*Carpinus*)
• Hazelnuts (the food)

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Corylus Avellana Pollen.

Corylus Avellana Pollen is generally classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. The primary risk is not the extract itself, but the potential for a systemic reaction (anaphylaxis) in the mother, which can lead to uterine contractions, placental abruption, or fetal distress due to oxygen deprivation.

• Initiation: Most guidelines recommend against starting a new course of immunotherapy during pregnancy.
• Maintenance: If a patient is already on a maintenance dose and is tolerating it well, the doctor may choose to continue treatment, as the risk of a reaction is lower during the maintenance phase than during the build-up phase.

It is not known whether the allergenic components of Corylus Avellana Pollen are excreted in human milk. However, since these are large proteins that are processed locally and enter the systemic circulation in very small amounts, it is considered unlikely to pose a risk to the nursing infant. The decision to continue immunotherapy while breastfeeding should be a risk-benefit discussion with your provider.

Immunotherapy with Corylus Avellana Pollen is effective in children for preventing the 'allergic march' (the progression from hay fever to asthma).

• Approved Age: Generally 5 years and older.
• Considerations: Children must be mature enough to sit still for the injection and, more importantly, to describe symptoms like an 'itchy throat' or 'funny feeling' that might signal a reaction.

Patients over age 65 may receive Corylus Avellana Pollen, but the safety profile is more complex.

• Comorbidities: Higher prevalence of heart disease and COPD increases the risk of complications from a systemic reaction.
• Medications: Elderly patients are more likely to be taking beta-blockers or ACE inhibitors, which complicate the treatment of anaphylaxis.
• Efficacy: Some studies suggest the immune system's 'plasticity' decreases with age, potentially making immunotherapy slightly less effective in older adults.

No dosage adjustments are required. The proteins in the extract are broken down into amino acids through normal metabolic processes and do not require renal filtration for clearance.

No dosage adjustments are required. The liver is not involved in the primary processing or clearance of allergenic extracts.

> Important: Special populations require individualized medical assessment.

Corylus Avellana Pollen contains several key allergenic proteins, most notably Cor a 1 (a PR-10 protein) and Cor a 8 (a lipid transfer protein).

1. 1Diagnostic Phase: The extract cross-links IgE antibodies on the surface of cutaneous mast cells. This triggers a signal transduction pathway involving tyrosine kinases (Syk and Fyn), leading to an influx of calcium and the release of pre-formed mediators like histamine and tryptase.
2. 2Therapeutic Phase: Immunotherapy induces 'immune deviation.' It promotes the expansion of Regulatory T-cells (Tregs) that secrete IL-10. This environment encourages B-cells to switch from producing IgE to producing IgG4. IgG4 acts as a 'decoy' or 'blocking' antibody, binding to the hazel pollen allergens before they can reach the IgE on mast cells.

• Onset of Action: For diagnostic testing, the effect is almost immediate (15-20 minutes). For immunotherapy, clinical improvement typically takes 6 to 12 months of consistent treatment.
• Duration of Effect: Successful immunotherapy can provide 'disease modification,' meaning the benefits persist for several years even after the injections are stopped.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous/Local) |

| Protein Binding | Primarily to IgE and IgG antibodies |

| Half-life | Proteins degraded within 24-48 hours locally |

| Tmax | 15-30 minutes (for local immune response) |

| Metabolism | Proteolytic degradation by macrophages |

| Excretion | Minimal renal/fecal excretion of intact proteins |

• Molecular Components: A mixture of proteins (10-70 kDa), carbohydrates, and pigments.
• Solubility: Highly soluble in aqueous buffers and saline.
• Drug Class: Non-Standardized Pollen Allergenic Extract [EPC]. It is also categorized under the broader EPC of 'Non-Standardized Food Allergenic Extract' in some databases due to the cross-reactivity with hazelnuts.

Corylus Avellana Pollen is part of the Allergenic Extracts therapeutic class. It is grouped with other tree pollens like Birch (Betula) and Oak (Quercus). While the prompt mentions Adrenocorticotropic Hormone [EPC], this is a distinct pharmacological class and is not the primary classification for pollen extracts.